Top

Published in:

01-04-2011 | Epidemiology

Bone mineral density and risk of postmenopausal breast cancer

Authors: Debjani Grenier, Andrew L. Cooke, Lisa Lix, Colleen Metge, Huimin Lu, William D. Leslie

Published in: Breast Cancer Research and Treatment | Issue 3/2011

Abstract

To determine if higher bone mineral density (BMD) is a risk factor for breast cancer in women age 50 years and older. 37,860 women ≥50-year old with no previous breast cancer diagnosis had baseline BMD assessment between January 1999 and December 2007. Cox proportional hazards models were created for time to a new breast cancer as a function of lumbar spine or femoral neck BMD quartile (1st = lowest as reference) with adjustment for relevant covariates. A secondary analysis was performed to look for an association with estrogen receptor-positive (ER-positive) breast cancers. 794 invasive and in situ breast cancers (484 ER-positive) occurred with a median follow up of 5.4 years. Increased breast cancer risk was seen for the 3rd and 4th quartiles of lumbar spine BMD with hazard ratios (HRs) of 1.26 (95% CI, 1.01–1.58) and 1.45 (95% CI, 1.16–1.81), respectively and for the 3rd quartile of femoral neck BMD with a HR of 1.33 (95% CI, 1.07–1.64). A test for linear trend showed that lumbar spine BMD (P < 0.001) and femoral neck BMD (P = 0.04) were associated with increased risk. Higher lumbar spine BMD was also associated with increased risk of ER-positive breast cancer with HR of 1.45 (95% CI, 1.08–1.94), and 1.68 (95% CI, 1.24–2.27) for women in the 2nd and 4th quartiles, respectively. A test for linear trend showed lumbar spine BMD was associated with increasing risk of ER-positive breast cancer (P = 0.003). Increased ER-positive breast cancer risk was seen for the 3rd quartile of femoral neck BMD with a HR of 1.43 (95% CI, 1.08–1.89). Higher lumbar spine and femoral neck BMD are associated with higher risk of breast cancer in women ≥50-year old. Lumbar spine and femoral neck BMD are associated with increased risk of ER-positive breast cancer.

Bray F, McCarron P, Parkin DM (2004) The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6(6):229–239PubMedCrossRef

American Cancer Society: cancer facts and figures. http://www.cancer.org

Cummings SR, Duong T, Kenyon E et al (2002) Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287(2):216–220PubMedCrossRef

Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333PubMedCrossRef

Bernstein L (2002) Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia 7(1):3–15PubMedCrossRef

Cauley JA, Gutai JP, Kuller LH et al (1988) Endogenous estrogen levels and calcium intake in postmenopausal women: relationships with cortical bone measures. JAMA 260(21):3150–3155PubMedCrossRef

Felson DT, Zhang Y, Hannan MT et al (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329(16):1141–1146PubMedCrossRef

Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285PubMedCrossRef

Santen RJ, Boyd NF, Chlebowski RT et al (2007) Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer 14(2):169–187PubMedCrossRef

10.

Tucker TC, Howe HL, Weir HK (1999) Certification for population-based cancer registries. J Regist Manag 26:24–27

11.

Leslie WD, MacWilliam L, Lix L et al (2005) A population-based study of osteoporosis testing and treatment following introduction of a new bone densitometry service. Osteoporos Int 16(7):773–782PubMedCrossRef

12.

Leslie WD, Caetano PA, MacWilliam LR et al (2005) Construction and validation of a population-based bone densitometry database. J Clin Densitom 8:25–30PubMedCrossRef

13.

Leslie WD, Metge C (2003) Establishing a regional bone density program: lessons from the Manitoba experience. J Clin Densitom 6:275–282PubMedCrossRef

14.

Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167(10 suppl):S1–S34PubMed

15.

Hansen KF, Binkley N, Christian R (2005) Interobserver reproducibility of criteria for vertebral body exclusion. J Bone Miner Res 20:501–508PubMedCrossRef

16.

Leslie WD (2006) The importance of spectrum bias on bone mineral density monitoring in clinical practice. Bone 39:361–368PubMedCrossRef

17.

van der Klift M, de Laet CE, Coebergh JW et al (2003) Bone mineral density and the risk of breast cancer; the Rotterdam study. Bone 32:211–216PubMedCrossRef

18.

Buist DS, Lacroix AZ, Barlow WE et al (2001) Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol 54(4):417–422PubMedCrossRef

19.

Zhang Y, Kiel DP, Kreger BE et al (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336(9):611–617PubMedCrossRef

20.

Lucas FL, Cauley JA, Stone RA (1998) Bone mineral density and risk of breast cancer: differences by family history of breast cancer. Study of Osteoporotic Fractures Research Group. Am J Epidemiol 148(1):22–29PubMed

21.

Chen Z, Arendell L, Aickin M (2008) Hip bone density predicts breast cancer risk independently of Gail score. Results from the Women’s Health Initiative. Cancer 113(5):907–915PubMedCrossRef

22.

Cauley JA, Song J, Dowsett SA (2007) Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors. Breast Cancer Res Treat 102(2):181–188PubMedCrossRef

23.

Stewart A, Kumar V, Torgerson DJ et al (2005) Axial BMD, change in BMD and bone turnover do not predict breast cancer incidence in early postmenopausal women. Osteoporosis 16(12):1627–1632CrossRef

24.

Kerlikowske K, Shepherd J, Creasman J et al (2005) Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst 97:368–374PubMedCrossRef

25.

Nelson RL, Turyk M, Kim J et al (2002) Bone mineral density and the subsequent risk of cancer in the NHANES I follow-up cohort. BMC Cancer 2(1):22PubMedCrossRef

26.

Tremollieres FA, Pouilles JM, Laparra J et al (2008) Bone mineral density at menopause does not predict breast cancer incidence. Osteoporos Int 19(10):1497–1504PubMedCrossRef

27.

Rosenberg LU, Einarsdottir K, Friman EI et al (2006) Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 15(12):2482–2488PubMedCrossRef

28.

Burshell AL, Song J, Dowsett SA et al (2008) Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. Curr Med Res Opin 24(3):807–813PubMedCrossRef

29.

Chlebowski RT, Kuller LH, Prentice RL (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573–587PubMedCrossRef

30.

Pieta B, Samulak D, Opala T et al (2009) Women’s lifestyle and the risk of breast tumors. Eur J Gynaecol Oncol 30(2):186–189PubMed

31.

Jacobi CE, de Bock GH, Siegerink B, et al. (2008) Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat, May 30 (Epub ahead of print)

Title: Bone mineral density and risk of postmenopausal breast cancer
Authors: Debjani Grenier
Andrew L. Cooke
Lisa Lix
Colleen Metge
Huimin Lu
William D. Leslie
Publication date: 01-04-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1138-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Catechol-O-methyltransferase Val158Met polymorphism in breast cancer risk

Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial

RACK1 promotes breast carcinoma migration/metastasis via activation of the RhoA/Rho kinase pathway

PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer

Significant association between ABCB1 gene C3435T polymorphism and breast cancer risk

Tetra-methoxystilbene modulates ductal growth of the developing murine mammary gland

Keynote webinar | Spotlight on antibody–drug conjugates in cancer